The cytokine receptor family type 2 (CRF2) comprises receptors for important immunomediators like interferons and interleukin-10 (IL-10
Introduction
The overall sequencing of the human genome gave rise to the discovery of many new genes. Thus, novel molecules with homology to the cytokine interleukin-10 (IL-10) have been identified, which were recently combined in the so-called IL-10 family. This family now comprises IL-10, IL-19, IL-20, IL-22, AK155 and the melanoma differentiation associated gene 7 (MDA-7). Common features of these molecules are (i) a homology in their amino acid sequences and their structures, (ii) their genomic localisation, and (iii) the homology of their receptors. All members of the IL-10 family are soluble, ␣-helical proteins whose amino acid sequences are about 20-30% homologous to IL-10. [1] [2] [3] [4] [5] The genes encoding human IL-19, IL-20 and MDA-7 have been mapped near the IL-10 gene on chromosome 1q31-32 in the so-called IL-10 gene cluster. 2 In contrast, the AK155 and IL-22-encoding genes are located on human chromosome 12q15 near the interferon (IFN)-␥ gene locus. 6 As known so far, the IL-10 homologues mediate their biological functions by binding to specific receptors that belong to the cytokine receptor family class 2 (CRF2). Further members of this receptor family are the receptor chains for type I and type II interferons and the mem-brane tether for coagulation factor VIIa. 7 The genes coding for this receptor family are predominantly clustered in the human genome as well. For instance, such clusters are localised on chromosome 21 (IFN-␥ receptor (R)2, IL-10R2, IFN-␣R1, IFN-␣R2) and on chromosome 6 (IFN-␥R1 and IL-20R1).
7 CRF2 members are usually transmembrane glycoproteins, whose extracellular domains consist of about 210 amino acids (aa) comprising two tandem fibronectin type III domains and have several conserved amino acid positions important for the secondary structure. In contrast, their intracellular domains vary in length and do not demonstrate striking sequence homology. 8 Two receptor chains, the ligandspecific R1 and R2, aggregate to form the final functional receptor complex. Studies on the IL-10 receptor complex have led to a concept of interaction that states distinct functions for both receptor chains. Thereby cytokine binding to the R1 chain allows the association with the R2 chain, provoking signal transduction via members of the Janus tyrosine kinase (Jak) family and the signal transducers and activators of transcription (STAT). [9] [10] [11] Recent studies on IL-22 revealed unique features of ligand-receptor interaction that are contrary to this scheme. The IL-22 receptor complex shares the R2 chain with the IL-10 receptor complex (IL-10R2, CRF2-4), representing the first example within this family of a common receptor chain. 10, [12] [13] [14] Furthermore, isolated IL-10R2 is able to bind IL-22, hence functioning in both, initial IL-22 binding and signalling as IL-22R1 does. Another binding mode has been demonstrated for IL-20. This cytokine binds only to cells that simultaneously express both chains of the receptor complex.
IL-10 is an important antiinflammatory and immunosuppressive cytokine which has been used to treat in various autoimmune diseases such as psoriasis, Crohn's disease, and rheumatoid arthritis. 15 Since the identification of the IL-10 homologues is very recent, the knowledge of their biology is still limited. It is obvious so far, that the sequence homology is not reflected by a shared biological function. IL-20 and IL-22 are suggested to have a role in inflammatory processes.
2,12 MDA-7 has been shown to provoke irreversible growth arrest of tumours by induction of apoptosis or differentiation. 16, 17 No biological function has been described for IL-19 and AK155 as yet. 1, 4 Hitherto, no receptors have been identified for IL-19, MDA-7 and AK155. It is reasonable to assume the missing receptors within the CRF2. To find novel receptors, we performed a bioinformatic search in human genome data for novel molecules with homology to IL-10R1. In this paper we describe the discovery of a new member of this cytokine receptor family, designated CRF2-soluble (s)1, which exclusively exists as a soluble protein. Furthermore, we demonstrate the existence of two splice forms and the specific tissue expression of these molecules.
Results

Genomic localisation and structure of CRF2-s1
To identify novel members of the CRF2, we performed a bioinformatic search in human genome databases for amino acid sequences with homology to that of human IL-10R1. This search revealed a prediction for a gene on chromosome 6q24.1-25.2 from GenBank entry AL050337 that spans a region of approximately 28 kilobases (kb). The locus of this novel homologue is situated less than 24 kb downstream of the IFN-␥R1 locus and 152 kb upstream of the IL-20R1 locus (Figure 1a ). The existence of the predicted cDNA sequence was confirmed by PCR analysis on reversely transcribed mRNA (RT-PCR) using specific primers. In order to isolate the full-length cDNA, we performed 5Ј and 3Ј RACE PCR using mRNA samples from mammary gland and placenta. This method generated two sequences with 1255 and 1351 base pairs (bp) length. Sequencing revealed that both sequences correspond to two different splice forms of this gene product (Figures 1a, b; 2). The long splice form, referred to as CRF2-s1-long, is composed of seven exons with the start site for protein synthesis lying within the second exon. The short form, referred to as CRF2-s1-short, misses the 96 bp-comprising exon IV (Figure 1a , b). All intron-exon boundaries match to the GT / AG rule ( Figure 1c) . The sequences of CRF2-s1-short and CRF2-s1-long are deposited with GenEMBL under accession numbers AJ313161 and AJ313162, respectively.
Properties of CRF2-s1 proteins
The cDNA species of CRF2-s1-short and CRF2-s1-long comprise an open reading frame of 693 and 789 bp length therefore encoding proteins of 231 and 263 amino acids (aa) (Figure 3 ). For both proteins an N-terminal signal peptide of 21 aa length with the cleavage site VAG-TQ is predicted. 18 The calculated molecular weights of CRF2-s1-short and CRF2-s1-long are 26.9 kDa and 30.5 kDa, respectively. Preliminary data of the recombinant pro- teins, however, revealed a real size of about 65 kDa and 70 kDa, suggesting glycosylation of both proteins (data not shown). The sequences of the predicted mature proteins contain five potential glycosylation sites similar to other CRF2 members ( Figure 3) . 19, 20 Alignment of the amino acid sequence of CRF2-s1 with those of other CRF2 members revealed an overall homology of approximately 30% only. However, the defined amino acids important for the secondary structure are conserved. For instance, all eight amino acids characteristic for the CRF2 are present in CRF2-s1 ( Figure 3) . Furthermore, the amino acids that are conservatively substituted between the known CRF2 members can be found in CRF2-s1. Like the other CRF2 members, CRF2-s1 is predicted to consist of two domains. The first domain has two conserved tryptophans and two conserved cysteines. The latter are assumed to form the first disulfide bond. The second sequences spanning the coding region were amplified using cDNA from placenta or mammary gland. Two sequences were generated that correspond to two CRF2-s1 splice forms. L: 100 bp ladder; P: placenta; MG: mammary gland. domain contains another cysteine pair which allows the formation of the second disulfide bond (Figure 3 ). Interestingly, unlike the other known CRF2 members, both CRF2-s1 forms have no transmembrane and no intracellular domain (Figure 3 ). We conclude that CRF2-s1 is solely a soluble receptor thereby differing from all other CRF2 members known so far. 
Genes and Immunity
Expression of CRF2-s1 in immune cells
Since most members of the CRF2 are receptors for molecules, whose major targets are immune cells, we investigated the expression of CRF2-s1 in leukocyte subpopulations from the peripheral blood. The quantitative analysis of both CRF2-s1 splice forms was performed by real time PCR. Although the lower detection levels in these experiments lay at 200 times lower expression level than that of the house-keeping gene hypoxanthine phosphoribosyltransferase-1 (HPRT-1), none of the CRF2-s1 variants was detected in freshly isolated monocytes, B cells, NK cells or T cells. Furthermore, kinetic studies demonstrated no induction of CRF2-s1 expression in these cells after cellspecific stimulation (data not shown).
Expression of CRF2-s1 in human tissues
Additionally, the expression patterns of both CRF2-s1 splice forms were analyzed in various human tissues. Figure 4 shows the expression levels relative to that of HPRT-1. The only tissue clearly expressing the long form was placenta. The expression of the short splice form is restricted, too. It is highly expressed in placenta and mammary gland and, at lower levels, in skin, spleen, thymus, and stomach. By increasing the sensitivity of real time PCR analysis, thereby decreasing the fidelity of quantification, slight CRF2-s1-long and CRF2-s1-short expression became detectable in mammary gland and intestine, respectively.
Discussion
Based on a bioinformatic search for IL-10R1 homologous sequences, we have identified a new human cytokine receptor, referred to as CRF2-s1. CRF2-s1 shares the main structural properties of CRF2 members therefore constituting a new member of this family. However, in contrast to all other members, CRF2-s1 exists exclusively as a soluble protein as it lacks a transmembrane and an intracellular domain. Due to alternative splicing, there are two forms of this soluble receptor, a short and a long variant.
Recently, this receptor was also found by the groups of J.-C. Renauld and S. V. Kotenko and designated 'CRF 2-10' / 'IL-22BP'. 21, 22 For various cytokine receptors, truncated, soluble forms are known. These are generated either by proteolytic cleavage of the membrane-bound receptor, or by alternative splicing of the same mRNA precursor. 23, 24 Distinct biological functions of such receptors variants have been demonstrated. By binding their specific ligands they either support or prevent the ligand action. Support of ligand action is due to protection from proteolytic cleavage and transport via the circulation. At sites with low concentrations of ligand and soluble receptor, the ligand can be released to act locally in specific tissues. 25, 26 A neutralizing effect of the soluble receptor can result from competition for ligand binding with the signalling membrane-bound counterpart. 27 This especially happens at sites of inflammation where the concentration of soluble receptors is high.
The expression of CRF2-s1 is strongly tissue-specific. Using real-time RT-PCR, none of the splice forms was detected in resting or stimulated immune cells from the peripheral blood. CRF2-s1-short expression was present in placenta, mammary gland and, at lower levels, in skin, stomach, spleen, and thymus. Expression of CRF2-s1-long is even more restricted being exclusively detectable in placenta. The strong expression in placenta let us suppose a role of this receptor in establishing and maintaining successful pregnancy. This may implicate a role in implantation and placental development or in modification of maternal immune responses to protect the semiallogeneic embryo from rejection. Selective suppression of maternal immunity is assumed to ensure an immunologically privileged microenvironment for the embryo. 28, 29 Apart from pregnancy, CRF2-s1 may have a role in limiting inflammation and immune responses.
Because of its homology to IL-10R1 it seems to be reasonable to look for the CRF2-s1 binding candidate(s) within the IL-10 family. As the members of the CRF2 are structurally related, the regions in the amino acid sequence responsible for ligand interaction should be conserved. 30, 31 Regarding IL-10R1, the ligand binding site has been mapped. 32 Extrapolating the binding site onto CRF2-s1, only 10% of the corresponding amino acids are identical or similar between CRF2-s1 and IL-10R1 ( Figure  3 ). Therefore, it is unlikely that CRF2-s1 binds the ligand of IL-10R1, IL-10. In contrast, there is 50% homology of these amino acids between CRF2-s1 and IL-20R1 or IL-22R1, which makes IL-20 and IL-22 more probable as putative ligands. Regarding the structure of CRF2-s1, a variation between both splice forms can be predicted. CRF2-s1-long has a 32-aa long insert next to the most important amino acids of the putative ligand binding site. Even if no other example is known within the CRF2 with such a sequence insertion, and no significant homology of this insert to other known proteins is found, it may be suggested that the different CRF2-s1 forms may bind to structurally different ligands. Regarding IL-22, it contains four putative disulfide bond-forming cysteines and has been postulated to form homodimers. In contrast, IL-20 has six putative disulfide bond-forming cysteines and probably exists as monomer. Considering the predicted structures, one would speculate that IL-22 is a promising binding candidate for CRF2-s1-short, and IL-20 or another monomeric IL-10 homologue may be a promising binding candidate for CRF2-s1-long. The former assumption was confirmed very recently by the groups of J-C Renauld and SV Kotenko. They showed IL-22 binding to, and prevention of, IL-22R-mediated signalling by the short form of this soluble CRF2 receptor. 21, 22 The biological function of IL-22 is only partly understood. IL-22 also exerts a proinflammatory action as injection of IL-22 into mice induced the production of acute-phase reactants. 12 Accordingly, neutralization of IL-22 by CRF2-s1-short might represent a mechanism in pregnancy to repress dangerous inflammation that could provoke rejection of the embryo. IL-20 also has a role in inflammation since it increases the constitutive and, more particularly, the IL-1␤-induced expression of genes involved in inflammatory responses. Newborn IL-20-transgenic mice show retarded growth and development and die within a few days after birth, suggesting the necessity of suppressed IL-20 activity during pregnancy. 2 However, extensive binding and functional studies are necessary to verify the ligand for CRF2-s1-long. To understand the role of both soluble receptor proteins during pregnancy and generally in inflammation, studies on appropriate transgenic or gene-deficient animals would be helpful.
Materials and methods
Bioinformatic analysis and cloning of CRF2-s1
A blastp search against the entire collection of proteins predicted from the human genome draft was performed based on default sequence parameters and entire amino acid sequence of human IL-10R1 using the gene prediction algorithm genescan. One prediction from GenBank entry AL050337.6 showed 26% overall identity to IL-10R1.
After identifying a corresponding mRNA in expressing tissues by specific RT-PCR, full length nucleotide sequence was generated from placenta and mammary gland-derived total RNA by 5Ј and 3Ј RACE PCR (GeneRacer; Invitrogen, Netherland) using the sequencespecific primers 5Ј-CCACAAGTCATGGAATTTCCACA CA-3Ј and 5Ј-CTCAGTCAACGCATGAGTCTCTGAAG C-3Ј and the following cycle conditions: hold 2 min at 94°C; 25 cycles with 30 s at 94°C, 30 s at 68°C, 1 min at 72°C; and final hold 10 min at 72°C. For specific amplification of the coding region of CRF2-s1-short and CRF2-s1-long the primers 5Ј-CACTTGCAACCATGATGCCTA AACA-3Ј and 5Ј-CCACAAGTCATGGAATTTCCACAC A-3Ј and the Advantage 2 PCR Enzyme System (Clontech Laboratories, Heidelberg, Germany) were used.
Isolation and stimulation of human blood cells
PBMC were isolated from citrated venous blood of healthy volunteers by standard density gradient centrifugation using Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden). Further purification of PBMC subpopulations was performed by magnetic cell sorting using depletion MACS systems (Miltenyi Biotec, Bergisch-Gladbach, Germany). Isolated cells were at least 92% pure as judged by flow cytometric analysis. Cells were cultured as described previously. 33 Stimulation of isolated cells was performed for 2, 6 and 18 h using 100 ng/mL lipopolysaccharide from E. coli 0127 B8 (Sigma-Aldrich Chemie, Deisenhofen, Germany) (monocytes), 0.001% (w/v) heat killed, formalin-fixed Staphylococcus aureus cells (PANSORBIN; Calbiochem-Novabiochem, Bad Soden, Germany) (B cells), 10 ng/mL IL-2/10 ng/mL IL-12 (R& D Systems, Wiesbaden-Nordenstadt, Germany) or anti-CD3 antibodies coated on culture vessel (Orthoclone; Cilag, Sulzbach, Germany) (T cells). Specific cell activation was confirmed by means of flow cytometry and ELISA (see below). 
Flow cytometric analysis
TNF-␣ quantification
To verify monocyte activation, the TNF-␣ concentration in culture supernatant was measured using Immulite automated ELISA (DPC Biermann, Bad Nauheim, Germany).
Quantitative gene expression analysis
Total RNA from isolated blood cells was prepared using Invisorb RNA Kit II (Invitek, Berlin, Germany) according to the supplier's specifications. Panels of mostly pooled total RNA from human tissues were obtained from Clontech Laboratories. The number of donors that each specific RNA was derived from was as follows: adrenal gland (6), bone marrow (69), brain (2), fetal brain (24), cerebellum (1), colon (2), heart (1), kidney (6), liver (1), fetal liver (63), lung (2), mammary gland (8), pancreas (9), PBMCs (4), placenta (7), prostate (19) , salivary gland (43), skeletal muscle (12) , skin (6), small intestine (2), spinal cord (13), spleen (6), stomach (2), testis (45), thymus (12) , thyroid gland (53), trachea (84), uterus (3). Reverse transcription of mRNA was performed as follows: 0.05 g/L total RNA of each sample were incubated in the presence of 5 ng/L oligo-d(T) [12] [13] [14] [15] [16] [17] [18] primers (Gibco BRL, Eggenstein, Germany) at 75°C for 5 min and cooled down on ice afterwards. After addition of first strand buffer (Gibco BRL), 1 unit/L of RNasin ribonuclease inhibitor (Promega, Mannheim, Germany), 10 mM dithiothreitol (Gibco BRL), 250 M of dATP, dTTP, dCTP and dGTP (Pharmacia Biotech, Uppsala, Sweden), and 5 units/L moloney murine leukemia virus reverse transcriptase (Gibco BRL) reaction took place at 42°C for 60 min and was stopped afterwards by heating to 95°C for 5 min. The samples were then analysed by TaqMan PCR using TaqMan universal master mix (Applied Biosystems, Weiterstadt, Germany) in the ABI Prism 7700 Sequence Detector System (Perkin-Elmer Cetus, Foster City, CA, USA). 34 The sequences and concentrations of primers and 6-carboxy-fluorescein (FAM) / 6-carboxytetramethyl-rhodamine (TAMRA) double-labelled probes were as follows:
CRF2-s1-short forward 5Ј-ACTGGCAACAGCAGTGTCTATTTT-3Ј 50 nM reverse 5Ј-CTTGAGTACCCCAACAGTCTTCTTT-3Ј 900 nM probe FAM-5Ј-TGCAGTACAAAATATATGGACAGAGACAATGGAA  AAA-3Ј-TAMRA  200 nM  CRF2-s1 long  forward 5Ј-AGGCTGCAGAACATTGGCTAA-3Ј  300 nM  reverse 5Ј-TTCACTGGTAAGGTCACAAGAGAGTT-3Ј  300 nM  probe FAM-5Ј-TGGACAGAGACAATGGAAAAATAAAGAAGACTG  TTG-3Ј-TAMRA  200 nM  HPRT-1  forward 5Ј-AGTCTGGCTTATATCCAACACTTCG-3Ј  300 nM  reverse 5Ј-GACTTTGCTTTCCTTGGTCAGG-3Ј  300 nM  probe FAM-5Ј-TTTCACCAGCAAGCTTGCGACCTTGA-3Ј-TAMRA  200 nM Thermal conditions in each of the 40 cycles were 15 s at 95°C and 1 min at 60°C. CRF2-s1-short and CRF2-s1-long expression data were calculated relative to that of the house-keeping gene HPRT-1.
